1
|
Takimura CK, Campos CAHM, Melo PHMC, Campos JC, Gutierrez PS, Borges TFC, Curado L, Morato SP, Laurindo FRM, Lemos Neto PA. Preclinical study of a biodegradable polymer-based stent with abluminal sirolimus release. Arq Bras Cardiol 2014; 102:432-40. [PMID: 24759951 PMCID: PMC4051445 DOI: 10.5935/abc.20140044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2013] [Accepted: 11/13/2013] [Indexed: 11/20/2022] Open
Abstract
Background Bioabsorbable polymer stents with drug elution only on the abluminal surface may
be safer than durable polymer drug-eluting stents. Objective To report the experimental findings with the InspironTM stent - a
bioabsorbable polymer-coated stent with sirolimus release from the abluminal
surface only, recently approved for clinical use. Methods 45 stents were implanted in the coronary arteries of 15 pigs. On day 28 after
implantation, angiographic, intracoronary ultrasonographic and histomorphological
data were collected. Five groups were analyzed: Group I (nine bare-metal stents);
Group II (nine coated with bioabsorbable polymer on the luminal and abluminal
surfaces); Group III (eight stents coated with bioabsorbable polymer on the
abluminal surface); Group IV (nine stents with bioabsorbable polymer and sirolimus
on the luminal and abluminal surfaces); and Group V (ten stents with bioabsorbable
polymer and sirolimus only on the abluminal surface). Results The following results were observed for Groups I, II, III, IV and V, respectively:
percentage stenosis of 29 ± 20; 36 ± 14; 33 ± 19; 22 ± 13 and 26 ± 15 (p = 0.443);
late lumen loss (in mm) of 1.02 ± 0.60; 1.24 ± 0.48; 1.11 ± 0.54; 0.72 ± 0.44 and
0.78 ± 0.39 (p = 0.253); neointimal area (in mm2) of 2.60 ± 1.99; 2.74
± 1.51; 2.74 ± 1.30; 1.30 ± 1.14 and 0.97 ± 0.84 (p = 0.001; Groups IV and V
versus Groups I, II and III); and percentage neointimal area of 35 ± 25; 38 ± 18;
39 ± 19; 19 ± 18 and 15 ± 12 (p = 0.001; Groups IV and V versus Groups I, II and
III). Injury and inflammation scores were low and with no differences between the
groups. Conclusion The InspironTM stent proved to be safe and was able to significantly
inhibit the neointimal hyperplasia observed on day 28 after implantation in
porcine coronary arteries.
Collapse
Affiliation(s)
- Celso Kiyochi Takimura
- Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| | - Carlos Augusto Homem M Campos
- Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| | | | - Julliana Carvalho Campos
- Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| | - Paulo Sampaio Gutierrez
- Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| | | | | | | | | | - Pedro Alves Lemos Neto
- Instituto do Coração, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| |
Collapse
|